Progress in Neuro-Psychopharmacology and Biological Psychiatry
Volume 17, Issue 5, September 1993, Pages 765-774
A preliminary trial of ascorbic acid as supplemental therapy for autism
References (22)
- et al.
A scale for rating symptoms of patients with the syndrome of autism in real life settings
J. Amer. Acad. Child Psychiat.
(1986) - et al.
Studies of 3-H dopamine in neostriatal membrane preparations: Effects of ascorbic acid
Life Science
(1983) - et al.
Ascorbic acid and the binding of DA agonists to neostriatal membrane preparations
Neurophannacol
(1983) - et al.
Inhibition of dopamine D-1 and D-2 binding sites in neuronal tissues by ascorbate
Neuropharmacol
(1981) - et al.
Ascorbate blocks amphetamine-induced turning behavior in rats with unilateral nigrostriatal lesions
Brain Res. Bull.
(1979) - et al.
Effects of ascorbic acid on neurochemical, behavioral, and physiological systems mediated by catecholamines
Life Science
(1979) Megavitamin and Orthomolecular Therapy in Psychiatry
Nutri. Rev.
(1974)- et al.
Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms
Amer. J. Psychiat.
(1984) - et al.
Pharmacology of 3H-apomorphine binding to bovine brain tissue
Biochem. Pharmacol.
(1981) Drug treatment of infantile autism: The post decade
Psychopharmacology in child and adolescent psychiatry
J. Amer. Acad. Child and Adoles. Psychiat.
(1988)
Cited by (138)
The protective role of prenatal administration of ascorbic acid on autistic-like behavior in a rat model of autism
2024, IBRO Neuroscience ReportsAscorbate and its transporter SVCT2: The dynamic duo's integrated roles in CNS neurobiology and pathophysiology
2024, Free Radical Biology and MedicineAn Update on Psychopharmacological Treatment of Autism Spectrum Disorder
2022, NeurotherapeuticsOxidative stress, metabolic and mitochondrial abnormalities associated with autism spectrum disorder
2020, Progress in Molecular Biology and Translational ScienceNeurobiology of vitamin C: Expanding the focus from antioxidant to endogenous neuromodulator
2019, Pharmacological ResearchCitation Excerpt :Moreover, the notion of a link between schizophrenia and DA itself remains tenuous and is well beyond any further speculation of a possible link to AA [25,161,162]. Neuromodulation of DA neurotransmission may better support suggestions of AA applications for autism [163], dyskinesia [164,165], catalepsy [166], and obstructive sleep apnea [167]. Besides dopamine, AA interacts with other monoamines such as serotonin (5-HT) [168] and acetylcholine (Ach) [169,170].
Copyright © 1993 Published by Elsevier Inc.